Diligence memo · auto-generated · as of July 2, 2026
CyMon Bio, Inc.
CyMon Bio, Inc. looks over-valued against its niche peers and is quiet on financing cadence.
Businessfiled
CyMon Bio, Inc. operates in Biotech / Pharma, based in AGOURA HILLS.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
CyMon Bio, Inc. has raised $922K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $922K on 2024-01-29.
Most recent recorded round closed around 2024-01-29.
Valuation (modeled)modeled
Provath models CyMon Bio, Inc. at approximately $5.4M (range $504K–$21M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.58× the median modeled value of Pre-Seed Biotech / Pharma companies in 2022–2024 (28 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 2.4 yr ago; this sector typically re-raises about every 15 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 29% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 28% of those peers.
Closest niche peers: Gaingels Oct Bio LLC, Gaingels Alto Pharmacy LLC, Pyros Pharmaceuticals, Inc., Allander Biotechnologies, Inc., EOF Bio LLC.
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.